Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
What is Chemical Works of Gedeon Richter. stock price today?▼
The current price of 0QFP.LSE is ft12,395 HUF — it has decreased by -1.39% in the past 24 hours. Watch Chemical Works of Gedeon Richter. stock price performance more closely on the chart.
What is Chemical Works of Gedeon Richter. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chemical Works of Gedeon Richter. stocks are traded under the ticker 0QFP.LSE.
What is Chemical Works of Gedeon Richter. market cap?▼
Today Chemical Works of Gedeon Richter. has the market capitalization of 2.31T
When is the next Chemical Works of Gedeon Richter. earnings date?▼
Chemical Works of Gedeon Richter. is going to release the next earnings report on May 12, 2026.
What is Chemical Works of Gedeon Richter. revenue for the last year?▼
Chemical Works of Gedeon Richter. revenue for the last year amounts to 2.54T HUF.
What is Chemical Works of Gedeon Richter. net income for the last year?▼
0QFP.LSE net income for the last year is 628B HUF.
Does Chemical Works of Gedeon Richter. pay dividends?▼
Yes, 0QFP.LSE dividends are paid annual. The last dividend per share was 509 HUF. As of today, Dividend Yield (FWD)% is 3.74%.
How many employees does Chemical Works of Gedeon Richter. have?▼
As of April 10, 2026, the company has 10,943 employees.
In which sector is Chemical Works of Gedeon Richter. located?▼
Chemical Works of Gedeon Richter. operates in the Industrials sector.
When did Chemical Works of Gedeon Richter. complete a stock split?▼
The last stock split for Chemical Works of Gedeon Richter. was on July 23, 2013 with a ratio of 10:1.
Where is Chemical Works of Gedeon Richter. headquartered?▼
Chemical Works of Gedeon Richter. is headquartered in Budapest, GB.